Literature DB >> 28469076

Stat3 regulates desmoglein 3 transcription in epithelial keratinocytes.

Xuming Mao, Michael Jeffrey T Cho, Christoph T Ellebrecht, Eric M Mukherjee, Aimee S Payne.   

Abstract

Pemphigus vulgaris (PV) is an epithelial blistering disease caused by autoantibodies to the desmosomal cadherin desmoglein 3 (DSG3). Glucocorticoids improve disease within days by increasing DSG3 gene transcription, although the mechanism for this observation remains unknown. Here, we show that DSG3 transcription in keratinocytes is regulated by Stat3. Treatment of primary human keratinocytes (PHKs) with hydrocortisone or rapamycin, but not the p38 MAPK inhibitor SB202190, significantly increases DSG3 mRNA and protein expression and correspondingly reduces phospho-S727 Stat3. Stat3 inhibition or shRNA-knockdown also significantly increases DSG3 mRNA and protein levels. Hydrocortisone- or rapamycin-treated PHKs demonstrate increased number and length of desmosomes by electron microscopy and are resistant to PV IgG-induced loss of cell adhesion, whereas constitutive activation of Stat3 in PHKs abrogates DSG3 upregulation and inhibits hydrocortisone and rapamycin's therapeutic effects. Topical hydrocortisone, rapamycin, or Stat3 inhibitor XVIII prevents autoantibody-induced blistering in the PV passive transfer mouse model, correlating with increased epidermal DSG3 expression and decreased phospho-S727 Stat3. Our data indicate that glucocorticoids and rapamycin upregulate DSG3 transcription through inhibition of Stat3. These studies explain how glucocorticoids rapidly improve pemphigus and may also offer novel insights into the physiologic and pathophysiologic regulation of desmosomal cadherin expression in normal epidermis and epithelial carcinomas.

Entities:  

Keywords:  Autoimmunity; Dermatology

Year:  2017        PMID: 28469076      PMCID: PMC5414550          DOI: 10.1172/jci.insight.92253

Source DB:  PubMed          Journal:  JCI Insight        ISSN: 2379-3708


  34 in total

1.  Stat3 links activated keratinocytes and immunocytes required for development of psoriasis in a novel transgenic mouse model.

Authors:  Shigetoshi Sano; Keith Syson Chan; Steve Carbajal; John Clifford; Mary Peavey; Kaoru Kiguchi; Satoshi Itami; Brian J Nickoloff; John DiGiovanni
Journal:  Nat Med       Date:  2004-12-12       Impact factor: 53.440

2.  Topical sirolimus for oral pemphigus vulgaris: 3 unresponsive cases.

Authors:  Angelique M Poot; Marcel F Jonkman
Journal:  J Am Acad Dermatol       Date:  2012-11       Impact factor: 11.527

3.  Targeted disruption of the mouse Stat3 gene leads to early embryonic lethality.

Authors:  K Takeda; K Noguchi; W Shi; T Tanaka; M Matsumoto; N Yoshida; T Kishimoto; S Akira
Journal:  Proc Natl Acad Sci U S A       Date:  1997-04-15       Impact factor: 11.205

4.  Serine phosphorylation and maximal activation of STAT3 during CNTF signaling is mediated by the rapamycin target mTOR.

Authors:  K Yokogami; S Wakisaka; J Avruch; S A Reeves
Journal:  Curr Biol       Date:  2000-01-13       Impact factor: 10.834

5.  Keratinocyte-specific ablation of Stat3 exhibits impaired skin remodeling, but does not affect skin morphogenesis.

Authors:  S Sano; S Itami; K Takeda; M Tarutani; Y Yamaguchi; H Miura; K Yoshikawa; S Akira; J Takeda
Journal:  EMBO J       Date:  1999-09-01       Impact factor: 11.598

6.  AZD9150, a next-generation antisense oligonucleotide inhibitor of STAT3 with early evidence of clinical activity in lymphoma and lung cancer.

Authors:  David Hong; Razelle Kurzrock; Youngsoo Kim; Richard Woessner; Anas Younes; John Nemunaitis; Nathan Fowler; Tianyuan Zhou; Joanna Schmidt; Minji Jo; Samantha J Lee; Mason Yamashita; Steven G Hughes; Luis Fayad; Sarina Piha-Paul; Murali V P Nadella; Morvarid Mohseni; Deborah Lawson; Corinne Reimer; David C Blakey; Xiaokun Xiao; Jeff Hsu; Alexey Revenko; Brett P Monia; A Robert MacLeod
Journal:  Sci Transl Med       Date:  2015-11-18       Impact factor: 17.956

7.  A nuclear factor for IL-6 expression (NF-IL6) is a member of a C/EBP family.

Authors:  S Akira; H Isshiki; T Sugita; O Tanabe; S Kinoshita; Y Nishio; T Nakajima; T Hirano; T Kishimoto
Journal:  EMBO J       Date:  1990-06       Impact factor: 11.598

8.  Phase I and biomarker study of OPB-51602, a novel signal transducer and activator of transcription (STAT) 3 inhibitor, in patients with refractory solid malignancies.

Authors:  A L Wong; R A Soo; D S Tan; S C Lee; J S Lim; P C Marban; L R Kong; Y J Lee; L Z Wang; W L Thuya; R Soong; M Q Yee; T M Chin; M T Cordero; B R Asuncion; B Pang; S Pervaiz; J L Hirpara; A Sinha; W W Xu; M Yuasa; T Tsunoda; M Motoyama; T Yamauchi; B C Goh
Journal:  Ann Oncol       Date:  2015-01-21       Impact factor: 32.976

9.  Desmocollin switching in colorectal cancer.

Authors:  K Khan; R Hardy; A Haq; O Ogunbiyi; D Morton; M Chidgey
Journal:  Br J Cancer       Date:  2006-10-31       Impact factor: 7.640

Review 10.  Genomic and computational approaches to dissect the mechanisms of STAT3's universal and cell type-specific functions.

Authors:  Andrew Paul Hutchins; Diego Diez; Diego Miranda-Saavedra
Journal:  JAKSTAT       Date:  2013-05-20
View more
  11 in total

1.  Keratinocyte cadherin desmoglein 1 controls melanocyte behavior through paracrine signaling.

Authors:  Christopher R Arnette; Quinn R Roth-Carter; Jennifer L Koetsier; Joshua A Broussard; Hope E Burks; Kathleen Cheng; Christine Amadi; Pedram Gerami; Jodi L Johnson; Kathleen J Green
Journal:  Pigment Cell Melanoma Res       Date:  2019-10-10       Impact factor: 4.693

Review 2.  Mechanisms of Autoantibody-Induced Pathology.

Authors:  Ralf J Ludwig; Karen Vanhoorelbeke; Frank Leypoldt; Ziya Kaya; Katja Bieber; Sandra M McLachlan; Lars Komorowski; Jie Luo; Otavio Cabral-Marques; Christoph M Hammers; Jon M Lindstrom; Peter Lamprecht; Andrea Fischer; Gabriela Riemekasten; Claudia Tersteeg; Peter Sondermann; Basil Rapoport; Klaus-Peter Wandinger; Christian Probst; Asmaa El Beidaq; Enno Schmidt; Alan Verkman; Rudolf A Manz; Falk Nimmerjahn
Journal:  Front Immunol       Date:  2017-05-31       Impact factor: 7.561

3.  Temporal Outcomes after Rituximab Therapy for Pemphigus Vulgaris.

Authors:  Napatra Tovanabutra; Christina E Bax; Rui Feng; Carolyn J Kushner; Aimee S Payne
Journal:  J Invest Dermatol       Date:  2021-10-26       Impact factor: 8.551

Review 4.  Pemphigus and Pemphigoid: From Disease Mechanisms to Druggable Pathways.

Authors:  Christoph T Ellebrecht; Damian Maseda; Aimee S Payne
Journal:  J Invest Dermatol       Date:  2021-10-29       Impact factor: 7.590

Review 5.  Desmosomal Cadherins in Health and Disease.

Authors:  Marihan Hegazy; Abbey L Perl; Sophia A Svoboda; Kathleen J Green
Journal:  Annu Rev Pathol       Date:  2021-08-23       Impact factor: 23.472

Review 6.  Pemphigus-A Disease of Desmosome Dysfunction Caused by Multiple Mechanisms.

Authors:  Volker Spindler; Jens Waschke
Journal:  Front Immunol       Date:  2018-02-01       Impact factor: 7.561

7.  SOX30 is a key regulator of desmosomal gene suppressing tumor growth and metastasis in lung adenocarcinoma.

Authors:  Xianglin Hao; Fei Han; Bangjin Ma; Ning Zhang; Hongqiang Chen; Xiao Jiang; Li Yin; Wenbin Liu; Lin Ao; Jia Cao; Jinyi Liu
Journal:  J Exp Clin Cancer Res       Date:  2018-05-31

Review 8.  Pemphigus: Current and Future Therapeutic Strategies.

Authors:  Dario Didona; Roberto Maglie; Rüdiger Eming; Michael Hertl
Journal:  Front Immunol       Date:  2019-06-25       Impact factor: 7.561

Review 9.  Current Clinical Trials in Pemphigus and Pemphigoid.

Authors:  Kentaro Izumi; Katja Bieber; Ralf J Ludwig
Journal:  Front Immunol       Date:  2019-05-03       Impact factor: 7.561

Review 10.  Tyrosine Kinases in Autoimmune and Inflammatory Skin Diseases.

Authors:  Kata P Szilveszter; Tamás Németh; Attila Mócsai
Journal:  Front Immunol       Date:  2019-08-09       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.